FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2408016393> ?p ?o ?g. }

• W2408016393 abstract "Background: Multi-parameter gene expression assays (MPAs) are widely used to estimate individual patient residual risk and to guide chemotherapy use in hormone-sensitive HER2-negative node-negative early breast cancer. These uses of MPAs have not yet been prospectively validated. OPTIMA aims to validate the use of MPA testing to predict chemotherapy sensitivity in a largely node-positive breast cancer population. Methods: OPTIMA is a partially blinded multi-center, phase 3 randomized controlled trial with an adaptive two-stage design. The preliminary phase (OPTIMA prelim) evaluated the performance of MPAs to identify a suitable test(s) to be used in the main efficacy trial and assessed the feasibility and acceptability of a large UK trial. Eligible patients are men or women aged 40 years or older who have surgically resected early stage breast cancer, which is ER-positive and HER2-negative and who have either 1-9 involved axillary lymph nodes or tumors of at least 30mm diameter. Randomization is to standard management (chemotherapy followed by endocrine therapy) or to MPA-directed treatment. Those with a tumor categorized as high-risk by the test will be assigned to standard management whilst those at low-risk will be treated with endocrine therapy alone. OPTIMA prelim used Oncotype DX as the primary discriminator; the main trial will use Prosigna (PAM50). The co-primary outcomes are (1) Invasive Disease Free Survival (IDFS) and (2) cost-effectiveness of test-directed therapy compared to standard practice. Secondary outcomes include IDFS in low-risk patients, distant disease free survival, breast cancer specific survival, overall survival and quality of life. An integrated qualitative recruitment study will identify and address challenges to recruitment and informed consent. Tumor blocks from all consenting participants will be banked allowing the performance of alternative MPA technologies to be evaluated. Recruitment of 4500 patients over 4 years will permit demonstration of 3% non-inferiority of test-directed treatment, with 5% significance and 85% power, assuming 3 years follow-up and a control arm 5-year IDFS of at least 85%. The addition of patients from OPTIMA prelim will allow non-inferiority to be assessed with 2.5% significance. Results: OPTIMA-prelim recruited 412 patients in 23 months from 35 sites. It confirmed the acceptability of randomization to patients with a 47% acceptance rate, and to clinicians and hence the feasibility of a large prospective trial of test-directed treatment running in 100-plus UK sites. It showed that investment into research on test-directed therapy, especially with Prosigna, should be of substantial value to the NHS. Conclusion: OPTIMA, as one of two large scale prospective trials validating the use of test-guided chemotherapy in node-positive hormone-sensitive early breast cancer will have a global impact on patient treatment. Recruitment into the main efficacy trial will commence in October 2015. Funding: Project funded by the UK NIHR HTA Programme (10/34/501). Views expressed are those of the authors and not those of the HTA Programme, NIHR, NHS or the DoH. Citation Format: Stein RC, Marshall A, Hall PS, Bartlett JMS, Rooshenas L, Campbell A, Cameron DA, Rea D, Macpherson I, Earl HM, Poole CJ, Francis A, Morgan A, Harmer V, Pinder SE, Stallard N, Donovan J, Hulme C, McCabe C, Hughes-Davies L, Makris A, Dunn JA. OPTIMA (optimal personalised treatment of early breast cancer usIng multi-parameter analysis), a prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-02-12." @default.
• W2408016393 created "2016-06-24" @default.
• W2408016393 creator A5000983072 @default.
• W2408016393 creator A5013882207 @default.
• W2408016393 creator A5014159829 @default.
• W2408016393 creator A5029391836 @default.
• W2408016393 creator A5029765726 @default.
• W2408016393 creator A5032037898 @default.
• W2408016393 creator A5040064457 @default.
• W2408016393 creator A5042726249 @default.
• W2408016393 creator A5043753160 @default.
• W2408016393 creator A5049636639 @default.
• W2408016393 creator A5063865167 @default.
• W2408016393 creator A5070994764 @default.
• W2408016393 creator A5072789711 @default.
• W2408016393 creator A5075464551 @default.
• W2408016393 creator A5078022391 @default.
• W2408016393 creator A5081370568 @default.
• W2408016393 creator A5082608082 @default.
• W2408016393 creator A5083955910 @default.
• W2408016393 creator A5084135937 @default.
• W2408016393 creator A5087790399 @default.
• W2408016393 creator A5090276267 @default.
• W2408016393 creator A5090707462 @default.
• W2408016393 date "2016-02-15" @default.
• W2408016393 modified "2023-09-27" @default.
• W2408016393 title "Abstract OT3-02-12: OPTIMA (optimal personalised treatment of early breast cancer usIng multi-parameter analysis), a prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions" @default.
• W2408016393 doi "https://doi.org/10.1158/1538-7445.sabcs15-ot3-02-12" @default.
• W2408016393 hasPublicationYear "2016" @default.
• W2408016393 type Work @default.
• W2408016393 sameAs 2408016393 @default.
• W2408016393 citedByCount "0" @default.
• W2408016393 crossrefType "proceedings-article" @default.
• W2408016393 hasAuthorship W2408016393A5000983072 @default.
• W2408016393 hasAuthorship W2408016393A5013882207 @default.
• W2408016393 hasAuthorship W2408016393A5014159829 @default.
• W2408016393 hasAuthorship W2408016393A5029391836 @default.
• W2408016393 hasAuthorship W2408016393A5029765726 @default.
• W2408016393 hasAuthorship W2408016393A5032037898 @default.
• W2408016393 hasAuthorship W2408016393A5040064457 @default.
• W2408016393 hasAuthorship W2408016393A5042726249 @default.
• W2408016393 hasAuthorship W2408016393A5043753160 @default.
• W2408016393 hasAuthorship W2408016393A5049636639 @default.
• W2408016393 hasAuthorship W2408016393A5063865167 @default.
• W2408016393 hasAuthorship W2408016393A5070994764 @default.
• W2408016393 hasAuthorship W2408016393A5072789711 @default.
• W2408016393 hasAuthorship W2408016393A5075464551 @default.
• W2408016393 hasAuthorship W2408016393A5078022391 @default.
• W2408016393 hasAuthorship W2408016393A5081370568 @default.
• W2408016393 hasAuthorship W2408016393A5082608082 @default.
• W2408016393 hasAuthorship W2408016393A5083955910 @default.
• W2408016393 hasAuthorship W2408016393A5084135937 @default.
• W2408016393 hasAuthorship W2408016393A5087790399 @default.
• W2408016393 hasAuthorship W2408016393A5090276267 @default.
• W2408016393 hasAuthorship W2408016393A5090707462 @default.
• W2408016393 hasConcept C112930515 @default.
• W2408016393 hasConcept C121608353 @default.
• W2408016393 hasConcept C126322002 @default.
• W2408016393 hasConcept C143998085 @default.
• W2408016393 hasConcept C2908647359 @default.
• W2408016393 hasConcept C3019080777 @default.
• W2408016393 hasConcept C530470458 @default.
• W2408016393 hasConcept C71924100 @default.
• W2408016393 hasConcept C99454951 @default.
• W2408016393 hasConceptScore W2408016393C112930515 @default.
• W2408016393 hasConceptScore W2408016393C121608353 @default.
• W2408016393 hasConceptScore W2408016393C126322002 @default.
• W2408016393 hasConceptScore W2408016393C143998085 @default.
• W2408016393 hasConceptScore W2408016393C2908647359 @default.
• W2408016393 hasConceptScore W2408016393C3019080777 @default.
• W2408016393 hasConceptScore W2408016393C530470458 @default.
• W2408016393 hasConceptScore W2408016393C71924100 @default.
• W2408016393 hasConceptScore W2408016393C99454951 @default.
• W2408016393 hasLocation W24080163931 @default.
• W2408016393 hasOpenAccess W2408016393 @default.
• W2408016393 hasPrimaryLocation W24080163931 @default.
• W2408016393 hasRelatedWork W10078604 @default.
• W2408016393 hasRelatedWork W12390373 @default.
• W2408016393 hasRelatedWork W12399243 @default.
• W2408016393 hasRelatedWork W12581806 @default.
• W2408016393 hasRelatedWork W17213031 @default.
• W2408016393 hasRelatedWork W17538324 @default.
• W2408016393 hasRelatedWork W17587699 @default.
• W2408016393 hasRelatedWork W2014385 @default.
• W2408016393 hasRelatedWork W2953784 @default.
• W2408016393 hasRelatedWork W7720014 @default.
• W2408016393 isParatext "false" @default.
• W2408016393 isRetracted "false" @default.
• W2408016393 magId "2408016393" @default.
• W2408016393 workType "article" @default.